# A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors

> **NCT01176500** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Colon Cancer
- Lung Cancer
- Cervical Cancer
- Renal Cell Carcinoma
- Uterine Cancer

## Interventions

- **DRUG:** (18)Fluciclatide

## Key facts

- **NCT ID:** NCT01176500
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-07-28
- **Primary completion:** 2011-11-18
- **Final completion:** 2011-11-18
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176500, "A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT01176500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*